Compare BW & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | DBVT |
|---|---|---|
| Founded | 1867 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.4M | 508.8M |
| IPO Year | N/A | N/A |
| Metric | BW | DBVT |
|---|---|---|
| Price | $5.25 | $19.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.50 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 2.9M | 767.2K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $721,285,000.00 | $5,502,000.00 |
| Revenue This Year | N/A | $1,768.71 |
| Revenue Next Year | $4.85 | $1,028.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 80.30 | N/A |
| 52 Week Low | $0.22 | $2.93 |
| 52 Week High | $7.77 | $26.19 |
| Indicator | BW | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 56.61 |
| Support Level | $4.73 | $18.46 |
| Resistance Level | $5.44 | $22.89 |
| Average True Range (ATR) | 0.50 | 1.82 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 36.34 | 41.17 |
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.